TY  - JOUR
A1  - Grottenthaler, Julia M.
A1  - Werner, Christoph R.
A1  - Steurer, Martina
A1  - Spengler, Ulrich
A1  - Berg, Thomas
A1  - Engelmann, Cornelius
A1  - Wedemeyer, Heiner
A1  - Hahn, Thomas von
A1  - Stremmel, Wolfgang
A1  - Pathil, Anita
A1  - Seybold, Ulrich
A1  - Schott, Eckart
A1  - Blessin, Usha
A1  - Sarrazin, Christoph
A1  - Welker, Martin-Walter
A1  - Harrer, Ellen
A1  - Scholten, Stefan
A1  - Hinterleitner, Clemens
A1  - Lauer, Ulrich Manfred
A1  - Malek, Nisar Peter
A1  - Berg, Christoph Peter
T1  - Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation
T2  - PLoS one
N2  - Objectives: The aim of this multicenter retrospective study was to investigate safety and efficacy of direct acting antiviral (DAA) treatment in the rare subgroup of patients with HCV/HIV-coinfection and advanced liver cirrhosis on the liver transplant waiting list or after liver transplantation, respectively.
Methods: When contacting 54 German liver centers (including all 23 German liver transplant centers), 12 HCV/HIV-coinfected patients on antiretroviral combination therapy were reported having received additional DAA therapy while being on the waiting list for liver transplantation (patient characteristics: Child-Pugh A (n = 6), B (n = 5), C (n = 1); MELD range 7–21; HCC (n = 2); HCV genotype 1a (n = 8), 1b (n = 2), 4 (n = 2)). Furthermore, 2 HCV/HIV-coinfected patients were denoted having received DAA therapy after liver transplantation (characteristics: HCV genotype 1a (n = 1), 4 (n = 1)).
Results: Applied DAA regimens were SOF/DAC (n = 7), SOF/LDV/RBV (n = 3), SOF/RBV (n = 3), PTV/r/OBV/DSV (n = 1), or PTV/r/OBV/DSV/RBV (n = 1), respectively. All patients achieved SVR 12, in the end. In one patient, HCV relapse occurred after 24 weeks of SOF/DAC therapy; subsequent treatment with 12 weeks PTV/r/OBV/DSV achieved SVR 12. One patient underwent liver transplantation while on DAA treatment. Analysis of liver function revealed either stable parameters or even significant improvement during DAA therapy and in follow-up. MELD scores were found to improve in 9/13 therapies in patients on the waiting list for liver transplantation; in only 2 patients a moderate increase of MELD scores persisted at the end of follow-up.
Conclusion: DAA treatment was safe and highly effective in this nation-wide cohort of patients with HCV/HIV-coinfection awaiting liver transplantation or being transplanted.
KW  - Liver transplantation
KW  - Antiretroviral therapy
KW  - HIV-1
KW  - Hepatitis C virus
KW  - Cirrhosis
KW  - Liver diseases
KW  - HIV
KW  - Antiretrovirals
Y1  - 2018
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/46560
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-465605
SN  - 1932-6203
N1  - Copyright: © 2018 Grottenthaler et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
VL  - 13
IS  - (6): e0197544
SP  - 1
EP  - 12
PB  - PLoS
CY  - Lawrence, Kan.
ER  -